TWI891942B - 氘化化合物 - Google Patents

氘化化合物

Info

Publication number
TWI891942B
TWI891942B TW110143066A TW110143066A TWI891942B TW I891942 B TWI891942 B TW I891942B TW 110143066 A TW110143066 A TW 110143066A TW 110143066 A TW110143066 A TW 110143066A TW I891942 B TWI891942 B TW I891942B
Authority
TW
Taiwan
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
dmt
Prior art date
Application number
TW110143066A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237565A (zh
Inventor
彼得 蘭茲
伊蘭 詹姆士
蒂芬妮 本威
澤拉 喬爾
馬莉 雷扎爾
Original Assignee
英商賽本英國有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/en
Priority claimed from US17/320,155 external-priority patent/US12042564B2/en
Application filed by 英商賽本英國有限公司 filed Critical 英商賽本英國有限公司
Priority to PCT/EP2021/083755 priority Critical patent/WO2022117640A1/en
Priority to EP21816489.5A priority patent/EP4255421A1/en
Priority to US18/252,949 priority patent/US12521370B2/en
Priority to GBGB2119021.0A priority patent/GB202119021D0/en
Publication of TW202237565A publication Critical patent/TW202237565A/zh
Priority to IL312859A priority patent/IL312859A/en
Priority to EP22818741.5A priority patent/EP4433049A1/en
Priority to US18/711,130 priority patent/US20250032450A1/en
Priority to CA3238583A priority patent/CA3238583A1/en
Priority to AU2022393234A priority patent/AU2022393234A1/en
Priority to PCT/EP2022/082486 priority patent/WO2023089132A1/en
Priority to MX2024005955A priority patent/MX2024005955A/es
Priority to JP2024529536A priority patent/JP2024540527A/ja
Priority to KR1020247020007A priority patent/KR20240110836A/ko
Priority to US18/056,771 priority patent/US12318477B2/en
Priority to CL2024001452A priority patent/CL2024001452A1/es
Priority to ZA2024/03906A priority patent/ZA202403906B/en
Priority to CONC2024/0007518A priority patent/CO2024007518A2/es
Priority to US19/192,691 priority patent/US20250262145A1/en
Publication of TWI891942B publication Critical patent/TWI891942B/zh
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110143066A 2020-12-01 2021-11-18 氘化化合物 TWI891942B (zh)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PCT/EP2021/083755 WO2022117640A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
EP21816489.5A EP4255421A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
US18/252,949 US12521370B2 (en) 2020-12-01 2021-12-01 Inhalable formulations
GBGB2119021.0A GB202119021D0 (en) 2021-11-18 2021-12-24 Injectable and inhalable formulations
PCT/EP2022/082486 WO2023089132A1 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
MX2024005955A MX2024005955A (es) 2021-11-18 2022-11-18 Formulaciones inyectables e inhalables.
JP2024529536A JP2024540527A (ja) 2021-11-18 2022-11-18 注射製剤及び吸入製剤
US18/056,771 US12318477B2 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
EP22818741.5A EP4433049A1 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
KR1020247020007A KR20240110836A (ko) 2021-11-18 2022-11-18 주사용 및 흡입용 제제
US18/711,130 US20250032450A1 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
AU2022393234A AU2022393234A1 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
IL312859A IL312859A (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
CA3238583A CA3238583A1 (en) 2021-11-18 2022-11-18 Injectable and inhalable formulations
CL2024001452A CL2024001452A1 (es) 2021-11-18 2024-05-15 Formulaciones inyectables e inhalables
ZA2024/03906A ZA202403906B (en) 2021-11-18 2024-05-20 Injectable and inhalable formulations
CONC2024/0007518A CO2024007518A2 (es) 2021-11-18 2024-06-14 Formulaciones inyectables e inhalables
US19/192,691 US20250262145A1 (en) 2021-11-18 2025-04-29 Injectable and inhalable formulations

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GB2018955.1 2020-12-01
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,938 2020-12-01
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 2021-03-22
GB2103981.3 2021-03-22
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
WOPCT/EP2021/060750 2021-04-23
CA3,118,556 2021-05-13
GB2106881.2A GB2595776B (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/320,155 2021-05-13
CA3118556A CA3118556A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
GB2106881.2 2021-05-13
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/320,155 US12042564B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
WOPCT/EP2021/062794 2021-05-13
PCT/EP2021/082227 WO2022117359A1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds

Publications (2)

Publication Number Publication Date
TW202237565A TW202237565A (zh) 2022-10-01
TWI891942B true TWI891942B (zh) 2025-08-01

Family

ID=88294961

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110143066A TWI891942B (zh) 2020-12-01 2021-11-18 氘化化合物

Country Status (8)

Country Link
EP (2) EP4031529B1 (https=)
JP (1) JP7834754B2 (https=)
CN (1) CN116761599B (https=)
AU (1) AU2021391581A1 (https=)
CA (1) CA3203020A1 (https=)
IL (1) IL303288A (https=)
TW (1) TWI891942B (https=)
WO (1) WO2022117359A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4433049A1 (en) * 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
EP4463440A1 (en) * 2022-01-14 2024-11-20 Cybin IRL Limited Tryptamine compositions and methods
US12264131B2 (en) * 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
AU2023361184A1 (en) 2022-10-13 2025-04-24 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
CN121038789A (zh) 2023-01-23 2025-11-28 赛本英国有限公司 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍
CN121194779A (zh) 2023-03-31 2025-12-23 赛本英国有限公司 包含单胺抗抑郁剂和短效致幻剂的组合
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337507A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
KR20220137081A (ko) * 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
MX2022014900A (es) * 2020-06-02 2023-03-27 Small Pharma Ltd Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Morris, P. E. et al., Indolealkylamine metabolism: Synthesis of deuterated indolealkylamines as metabolic probes, Journal of Labelled Compounds and Radiopharmaceuticals , 33(6), 1993, 455-465. *

Also Published As

Publication number Publication date
CN116761599A (zh) 2023-09-15
WO2022117359A1 (en) 2022-06-09
CA3203020A1 (en) 2022-06-09
IL303288A (en) 2023-07-01
EP4275753B1 (en) 2026-03-18
CN116761599B (zh) 2025-05-30
EP4031529A1 (en) 2022-07-27
JP2023551058A (ja) 2023-12-06
EP4275753A2 (en) 2023-11-15
EP4031529C0 (en) 2023-09-27
EP4275753A3 (en) 2023-12-27
AU2021391581A1 (en) 2023-07-06
JP7834754B2 (ja) 2026-03-24
EP4031529B1 (en) 2023-09-27
TW202237565A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
TWI891942B (zh) 氘化化合物
US12251371B2 (en) Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP3873883B1 (en) Method of synthesis
US11773062B2 (en) Deuterated compounds
EP4255421A1 (en) Inhalable formulations
US20220169606A1 (en) Compositions and compounds for bioanalysis
HK40103232A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40078818B (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40078818A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
CN116056763A (zh) 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物
GB2605144A (en) Deuterated compounds
HK40060666A (en) Method of synthesis
HK40060666B (en) Method of synthesis
HK40056359A (en) Compounds
HK40056359B (en) Compounds